Corsee Sanders, Ph.D.

Corsee Sanders, Ph.D.

Dr. Sanders has over 25 years of experience in global Pharma and Biotech Research and Development including senior executive roles overseeing diverse aspects of early-to-late development programs in both large and small organizations. Her experience spans the therapeutic areas of oncology, immunology, pulmonary, rheumatology, respiratory, neurology, ophthalmology, cardiovascular, inflammatory bowel disease, endocrinology, and infectious disease. Her primary focus areas are in Strategic and Development Operations, Portfolio Strategy, and Quantitative Sciences.

Most recently Dr. Sanders served on the Executive Committee of Juno Therapeutics’ CEO, as the Executive Vice President of Strategic and Development Operations, before transitioning to the strategic advisor to the Celgene office of the CMO, upon Celgene’s acquisition of Juno.

At Juno Therapeutics, she led multiple corporate-level organizations, including corporate project leadership and management, development operations, quantitative sciences, operational excellence, and CAR T patient operations.

Prior to joining Juno, Dr. Sanders was Senior Vice President at Hoffman-La Roche, as global head of clinical operations and industry collaboration, and before that, as global head of biometrics and development innovation. She was a member of the late stage portfolio committee, co-chair of the Roche-Chugai joint portfolio management committee and vice-chair of the Board of Directors of TransCelerate Inc. At Genentech, Inc. Dr. Sanders served in several senior leadership roles, including oversight of biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, development information technology, bio-sample management and development innovation. Dr. Sanders and her teams made significant contributions to programs across the early-to-late development portfolio. She was instrumental in the development and submission of Herceptin and its companion diagnostic, Herceptest. Dr. Sanders also directly contributed and/or led the planning and execution of Claritin, Rituxan, TNKase, Cathflo, Xolair, Avastin, Tarceva, Lucentis, Zelboraf, Perjeta, Erivedge, Gazyva, Kadcyla, Ocrevus, Hemlibra, and JCAR017, a CAR T cell therapy for NHL.

Dr. Sanders currently serves on the Board of Trustees of the Fred Hutchinson Cancer Center Research Center.  She is also on the Board of Directors of Molecular Templates, a biotech company developing Engineered Toxin Bodies to create novel drugs for cancer, and  AbGenomics, a pioneering organization with scientists seeking new and innovative ways to prevent, diagnose, and treat cancer, HIV/AIDS and other life-threatening diseases. She is also on the Life Science Council of Springboard Enterprises, a network of innovators, investors, and influencers, helping women build and lead big businesses.

Dr. Sanders holds Bachelor’s and Master’s degrees in Statistics from the University of the Philippines. She received a Master’s degree and Doctorate in Statistics from the Wharton School at the University of Pennsylvania.